| Company Name: | Regeneron Pharmaceuticals, Inc. | | Ticker Symbol: | REGN | | | WWW Address: | www.regeneron.com | | CEO: | Dr. Leonard S. Schleifer, M.D., Ph.D. | | No. of Employees: | 919 | | Common Issue Type: | CS | | Business Description: | The Company is engaged in the research, development, and commercialization of therapeutics to treat human disorders and conditions.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 18.5 |  -0.16 | 18.5 | 18.51 | 18.69 | 18.87 | 18.34 | 203528 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,489.3 | 80.5 | 1.26 | -1.05 | 0.00 | 0.0 | 0.0 | 23.49 - 11.81 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 18.66 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1,460.1 | mil |
| Latest Shares Outstanding | 80.5 | mil |
| Earnings pS (EPS) | -1.05 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 259,474 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 71.8 | mil |
| Float as % of Shares Outstanding | 89.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 15.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 112.50 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -25.0 | % |
| Pre-Tax Profit Margin | -20.6 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | -8.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -13.4 | % |
| Current Ratio | 4.0 | |
| Leverage Ratio (Assets/Equity) | 1.8 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.15 | |
| LT Debt/Total Capital | 13.0 | % |
| Working Capital pS | 4.32 | $ |
| Cash pS | 3.11 | $ |
| Book-Value pS | 5.25 | $ |
| Tangible Book-Value pS | 5.25 | $ |
| Cash Flow pS | -0.66 | $ |
| Free Cash Flow pS | -1.89 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.56 | |
| Price/Tangible Book Ratio | 3.56 | |
| Price/Cash Flow | -28.3 | |
| Price/Free Cash Flow | -9.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.1 | 100 | 9,064 | 5,801 |
| 4 Weeks | 19.96 | 15.02 | 15.70 | 18.9 | 111 | 7,771 | 132,103 |
| 13 Weeks | 23.49 | 15.02 | 22.33 | -16.4 | 78 | 5,665 | 345,564 |
| 26 Weeks | 23.49 | 14.91 | 15.27 | 22.2 | 102 | 5,171 | 646,355 |
| 52 Weeks | 23.49 | 11.81 | 15.46 | 20.7 | 98 | 5,033 | 1,253,123 |
| YTD | 23.49 | 11.81 | - | 1.6 | 83 | 5,102 | 1,158,166 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 18.75 | 18.99 | 18.34 | 18.54 | 17.35 | 1.26 | 1.14 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 18.36 | 26.1 | 65.04 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 10.59 | NA | 116.59 |
| R&D | 19.85 | NA | 32.62 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 43.7 | 48.6 | 90.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.26 | 0.26 | 0.54 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 65.34 |
| Current Ratio | 6.2 |
| Quick Ratio (Acid Test) | 6.1 |
| Liquidity Ratio (Cash) | 5.67 |
| Receivables Turnover | 8.9 |
| Average Collection Period | 40 |
| Working Capital/Equity | 104.5 |
| Working Capital pS | 5.47 |
| Cash-Flow pS | -0.89 |
| Free Cash-Flow pS | -1.55 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.14 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 37.5 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 40.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 1.32 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.25 |
| Tobin's Q Ratio | 2.18 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -15.74 |
| Enterprise Value (EV)/Free Cash Flow | -9.87 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.56 |
| Price/Book Ratio - LTM | 3.56 |
| Price/Cash Flow Ratio | -28.3 |
| Price/Free Cash Flow Ratio - LTM | -9.9 |
| Price/Sales Ratio | 4.72 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.05 |
| Tangible Book Value pS - LTM | 5.25 |
| Book Value pS - LTM | 5.25 |
| Capital Invested pS | 5.20 |
| Cash pS - LTM | 3.11 |
| Cash Flow pS - LTM | -0.66 |
| Free Cash Flow pS - LTM | -1.89 |
| Earnings pS (EPS) | -1.05 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -51.98 |
| Free Cash Flow Margin 5YEAR AVG | -15.89 |
| Net Profit Margin | -34.7 |
| Net Profit Margin - 5YEAR AVRG. | -51.7 |
| Equity Productivity | 0.57 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.57 |
| Return on Capital Invested (ROCI) | -19.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -17.3 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | -12.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | -11.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -25.0 |
| EBIT Margin - LTM | -20.4 |
| Pre-Tax Profit Margin | -33.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -51.4 |
| Effective Tax Rate | -2.9 |
| Effective Tax Rate - 5YEAR AVRG. | -0.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 53 |
| Revenue per Employee | 259,474 |
| Net Income per Employee | -90,000 |
| Average Collection Period | 53 |
| Receivables Turnover | 8.9 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 15.17 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.54 |
| Fixed Assets Turnover | 1.60 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 0.96 |
| Revenue per $ Plant | 2.71 |
| Revenue per $ Common Equity | 0.57 |
| Revenue per $ Capital Invested | 0.57 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 20.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 23.3 |
| Research & Devlopment (R&D) as % of Revenue | 116.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 116.6 |
|
|  
| | |  |  | |
| |